Neridronate (Synonyms: Neridronate) |
| Catalog No.GC36723 |
Le néridronate est un aminobisphosphonate, autorisé en Italie pour le traitement de l'ostéogenèse imparfaite (OI) et de la maladie osseuse de Paget (PDB). Le néridronate est également efficace dans d'autres maladies du squelette telles que l'ostéoporose, l'algodystrophie, l'hypercalcémie maligne et les métastases osseuses.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 79778-41-9
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Neridronate is an aminobisphosphonate, licensed in Italy for the treatment of osteogenesis imperfecta (OI) and Paget's disease of bone (PDB). Neridronate is effective also in other skeletal diseases such as osteoporosis, algodystrophy, hypercalcemia of malignancy, and bone metastases[1][2].
[1]. Gatti D, et al. Clinical development of neridronate: potential for new applications. Ther Clin Risk Manag. 2013;9:139-47. [2]. Guiducci L, et al. Monthly Intramuscular Neridronate for the Treatment of Postmenopausal Osteoporosis: Results of a 6-Year Prospective Italian Study. Int J Endocrinol. 2019 Feb 6;2019:9802827.
Average Rating: 5 (Based on Reviews and 18 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *